Alexion Pharmaceuticals, Inc.
 (ALXN)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Wed, Feb. 3, 8:46 AM
    • Alexion Pharmaceuticals (NASDAQ:ALXN) Q4 results ($M): Total Revenues: 700.9 (+16.9%); Net Product Sales: 700.4 (+16.8%); Soliris Sales: 688.5 (+14.8%); Kanuma Sales: 336.
    • Net Income: 66.6 (-56.6); EPS: 0.29 (-61.8%).
    • 2016 Guidance: Total Revenues: $3.05B - 3.1B; Soliris: $2.900B - 2.925B; Metabolic Franchise: $150M - 175M; EPS: $5.00 - 5.20.
    • Shares are down 5% premarket on light volume. Revenues were slightly short of consensus.
    • Previously: Alexion Pharmaceuticals beats by $0.03, misses on revenue (Feb. 3)
    | Wed, Feb. 3, 8:46 AM
  • Wed, Feb. 3, 6:32 AM
    • Alexion Pharmaceuticals (NASDAQ:ALXN): Q4 EPS of $1.13 beats by $0.03.
    • Revenue of $700.87M (+16.9% Y/Y) misses by $1.82M.
    • Press Release
    | Wed, Feb. 3, 6:32 AM
  • Tue, Feb. 2, 5:30 PM
    | Tue, Feb. 2, 5:30 PM | 4 Comments
  • Wed, Jan. 27, 3:30 PM
    • As if biotech investors need reminding, biotechs (and healthcare stocks) are getting some rude treatment today, the market's foul mood notwithstanding. The Nasdaq Composite Index is down 2.5%,but the SPDR S&P Biotech ETF (XBI -4.7%) almost twice as much. The iShares Nasdaq Biotechnology ETF (IBB -3.5%) is faring a bit better, but still down more than the broad market.
    • Only Biogen and Abbott have bucked the trend.
    • Sample of tickers: (AMGN -2.5%)(BIIB +5.7%)(CELG -3.9%)(GILD -3.3%)(ALXN -1.2%)(ABT +0.3%)(BMY -1.8%)(MRK -3%)(VRX -4%)(PFE -0.9%)
    • ETFs: BIB, BIS, CNCR
    | Wed, Jan. 27, 3:30 PM | 56 Comments
  • Fri, Jan. 22, 8:23 AM
    • Credit Suisse analysts have been very busy lately with a long list of initiations: Acceleron Pharma (NASDAQ:XLRN) Outperform with $50 (47% upside) price target; BioMarin Pharmaceutical (NASDAQ:BMRN) Outperform with $110 (36% upside) price target; Amgen (NASDAQ:AMGN) Outperform with $205 (34% upside) price target.
    • Celgene (NASDAQ:CELG) Outperform with $149 (41% upside) price target; Coherus Biosciences (NASDAQ:CHRS) Outperform with $25 (79% upside) price target; Gilead Sciences (NASDAQ:GILD) Outperform with $125 (40% upside) price target.
    • Regeneron Pharmaceuticals (NASDAQ:REGN) Neutral with $552 (19% upside) price target; Vertex Pharmaceuticals (NASDAQ:VRTX) Outperform with $151 (59% upside) price target; Alnylam Pharmaceuticals (NASDAQ:ALNY) Outperform with $154 (117% upside) price target.
    • Alexion Pharmaceuticals (NASDAQ:ALXN) Neutral rating with $201 (29% upside) price target; Biogen (NASDAQ:BIIB) Neutral with $322 (23% upside) price target; XenoPort (NASDAQ:XNPT) Underperform with $4 (16% downside risk) price target.
    • PTC Therapeutics (NASDAQ:PTCT) Outperform with $36 (33% upside) price target; Mesoblast Limited (NASDAQ:MESO) Outperform with $10 (92% upside) price target and Incyte (NASDAQ:INCY) Outperform with $110 (49% upside) price target.
    | Fri, Jan. 22, 8:23 AM | 3 Comments
  • Wed, Jan. 20, 1:47 PM
    • It appears that biotech investors have had enough of the sidelines. Many tickers are showing bullish reversals.
    • Representative tickers: (RLYP +15.3%)(CELG +2.6%)(AMGN +0.2%)(BIIB -1.6%)(ALXN -0.6%)(VRTX +0.2%)(IBB +0.8%)(XBI +2.1%)
    | Wed, Jan. 20, 1:47 PM | 20 Comments
  • Wed, Jan. 20, 11:36 AM
    • To point out the obvious, the biotech sector has been unable to fight off the widespread selling. The iShares Nasdaq Biotech Index Fund (IBB -1.8%) is down again, albeit on modestly higher volume. It's down over 21% since late December.
    • Representative tickers: (GILD -1.7%)(CELG +0.7%)(BIIB -2.7%)(AMGN -0.6%)(ALXN -2.8%)
    | Wed, Jan. 20, 11:36 AM | 17 Comments
  • Dec. 8, 2015, 11:31 AM
    • The FDA approves Alexion Pharmaceuticals' (ALXN +3.7%) Orphan Drug- and Breakthrough Therapy-tagged sebelipase alfa, branded as Kanuma, for the treatment of lysosomal acid lipase (LAL) deficiency, a rare genetic disorder whereby the body fails to produce enough of the LAL enzyme. LAL plays a key role in breaking down fatty material so the lack of it leads to the buildup of fat in the organs which leads to a multitude of health problems, including life-threatening organ failure.
    • Kanuma is an enzyme replacement therapy that is a recombinant form of the human LAL protein (rhLAL). It is produced by genetically engineered chickens that possess a recombinant DNA construct that is responsible for producing rhLAL in their egg whites, which are refined to extract the rhLAL protein.
    • Kanuma is administered once per week via intravenous infusion in patients with rapidly progressing LAL deficiency presenting in the first six months of life. It is administered every other week in all other patients.
    | Dec. 8, 2015, 11:31 AM
  • Dec. 3, 2015, 1:46 PM
    • Britain's National Institute for Health and Care Excellence (NICE), which advises the National Health Service (NHS) on costs, procedures and technologies with the aim of better managing the cost/benefit of services, thinks Alexion Pharmaceuticals' (ALXN -3.9%) Strensiq (asfotase alfa) is a bit too expensive for its tastes. The enzyme replacement therapy for pediatric-onset hypophosphatasia, affecting only seven people a year there, is priced at a hefty ₤366,912 ($552,000).
    • NICE says the company has yet to provide an adequate justification for the high price. Luckily for Alexion, its decision is still in the draft stage and is open to further consultation. The company will, no doubt, take advantage of the opportunity to try to change NICE's opinion.
    • Alexion is not alone. A few weeks ago, NICE rejected Amgen's (AMGN -3.4%) Repatha (evolocumab) saying, among other things, that it doubted the company's cost-effectiveness data.
    • Previously: Advisor to Britain's NHS gives thumbs down to Amgen's Repatha (Nov. 18)
    | Dec. 3, 2015, 1:46 PM | 1 Comment
  • Oct. 29, 2015, 12:13 PM
    • Alexion Pharmaceuticals (ALXN +1%) Q3 results: Revenues: $666.6M (+20.1%); COGS: $54.1M (+4.2%); R&D Expense: $165.7M (+64.5%); SG&A: $212.5M (+34.7%); Operating Income: $154.6M (-34.7%); Net Loss: ($183.8M) (-203.4%); Loss Per Share: ($0.81) (-192.0%); Quick Assets: $1,458.5M (-25.6%).
    • 2015 Guidance: Total Revenues: $2.6B from $2.6B - 2.62B; Non-GAAP EPS: $4.92 - 4.97 from $4.70 - 4.80.
    | Oct. 29, 2015, 12:13 PM
  • Oct. 29, 2015, 6:32 AM
    • Alexion Pharmaceuticals (NASDAQ:ALXN): Q3 EPS of $1.16 beats by $0.15.
    • Revenue of $666.64M (+20.1% Y/Y) in-line.
    | Oct. 29, 2015, 6:32 AM
  • Oct. 28, 2015, 5:30 PM
  • Oct. 23, 2015, 5:43 PM
    • Top gainers, as of 5.25 p.m.: ALXN +2.1%. TVIX +1.9%. OCUL +1.5%. MNKD +0.8%.
    • Top losers, as of 5.25p.m.: ZINC -9.3%. ZIONW -3.8%. SBGL -2.6%. ERIC -1.9%.
    | Oct. 23, 2015, 5:43 PM
  • Oct. 23, 2015, 3:56 PM
    • The FDA approves Alexion Pharmaceuticals' (ALXN +2.6%) Breakthrough Therapy-tagged Strensiq (asfotase alfa) for the treatment of perinatal, infantile and juvenile-onset hypophosphatasia (HPP), a rare and sometimes fatal metabolic bone disease.
    • Strensiq is a bone-targeted enzyme replacement therapy. It is designed to address the underlying cause of HPP, a deficiency in alkaline phosphatase.
    • HPP is an inherited disorder that affects multiple systems of the body. It is characterized by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities, in addition to systemic complications like profound muscle weakness, seizures, pain and respiratory failure leading to premature death in infants. It affects ~1 in 100K newborns.
    • Strensiq was cleared in the EU in September and in Japan in July.
    • Previously: Alexion Pharma's Strensiq cleared in the EU for ultra-rare metabolic disease (Sept. 1)
    | Oct. 23, 2015, 3:56 PM
  • Oct. 9, 2015, 10:00 AM
    • Thermo Fisher Scientific (TMO +0.3%) initiated with Buy rating and $145 (15% upside) price target by Argus.
    • Fate Therapeutics (FATE +0.4%) initiated with Outperform rating and $8 (41% upside) price target by Raymond James.
    • Ocata Therapeutics (OCAT +2.1%) initiated with Outperform rating and $8 (66% upside) price target by Raymond James.
    • Eli Lilly (LLY +2.8%) upgraded to Outperform from Neutral by Credit Suisse. Price target raised to $105 (22% upside) from $89.
    • Abbott Laboratories (ABT +1%) upgraded to Overweight from Equal Weight by Barclays. Price target lowered to $52 (26% upside) from $55.
    • NuVasive (NUVA -1.6%) upgraded to Buy from Hold by Canaccord Genuity. Price target raised to $58 (16% upside) from $52.
    • Amicus Therapeutics (FOLD +5.4%) upgraded to Buy from Neutral with an $8 (11% upside) price target by Chardan Capital.
    • Bluebird bio (BLUE +1.5%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target maintained at $143 (61% upside).
    • Pfizer (PFE +0.5%) upgraded to Outperform from Equal Weight by Morgan Stanley. Price target raised to $38 (15% upside) from $35.
    • Vertex Pharmaceuticals (VRTX +1.2%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $148 (35% upside) from $118.
    • Alexion Pharmaceuticals (ALXN -0.2%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $211 (29% upside) from $186.
    | Oct. 9, 2015, 10:00 AM | 12 Comments
  • Sep. 18, 2015, 10:11 AM
    • Anthera Pharmaceuticals (ANTH +3.3%) initiated with Buy rating and $15 (56% upside) price target by Citi.
    • Trovagene (TROV +4.2%) initiated with Buy rating and $10 (47% upside) price target by Cantor Fitzgerald.
    • Bruker (BRKR -1.1%) initiated with Equal Weight rating and $21 (16% upside) price target by Morgan Stanley.
    • Align Technology (ALGN -0.8%) initiated with Outperform rating and $70 (21% upside) price target by Leerink.
    • WebMD (WBMD -0.8%) upgraded to Outperform from Market Perform by Cowen & Co. Price target raised to $53 (29% upside) from $42.
    • Dentsply (XRAY -0.7%) upgraded to Outperform from Market Perform by Baird. Price target raised to $61 (15% upside) from $58.
    • Dentsply (XRAY -0.7%) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $70 (32% upside) from $56.
    • Vertex Pharmaceuticals (VRTX -4.2%) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $150 (16% upside) from $120.
    • Sirona Dental Systems (SIRO -0.8%) downgraded to Equal Weight by Morgan Stanley.
    • Amicus Therapeutics (FOLD -0.1%) downgraded to Neutral from Buy by Chardan Capital Markets. Price target is $17.50 (0% upside).
    • Raptor Pharmaceuticals (RPTP -0.7%) downgraded to Neutral from Buy by Citi. Price target lowered to $8 (16% upside) from $20.
    • Alexion Pharmaceuticals (ALXN -0.7%) downgraded to Equal Weight from Overweight by Barclays. Price target lowered to $205 (23% upside) from $220.
    | Sep. 18, 2015, 10:11 AM | 5 Comments
Company Description
Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Sector: Healthcare
Industry: Biotechnology
Country: United States